Splicing regulator SLU7 is essential for maintaining liver homeostasis

Journal of Clinical Investigation

Volumn 124, Issue 7, 2014, Pages 2909-2920

  Elizalde, María ^a   Urtasun, Raquel ^a   Azkona, María ^a   Latasa, María U ^a   Goñi, Saioa ^a   García Irigoyen, Oihane ^a   Uriarte, Iker ^b   Segura, Victor ^a   Collantes, María ^c   Di Scala, Mariana ^a   Lujambio, Amaia ^d,e   Prieto, Jesús ^a,b   Ávila, Matías A ^a,b   Berasain, Carmen ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 4ALPHA; PROTEIN; SERINE ARGININE RICH PROTEIN; SERINE ARGININE RICH SPLICING FACTOR 3; SLU7 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE METABOLISM; CELL DEDIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DISORDERS OF LIPID METABOLISM; ESSENTIAL GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPID HOMEOSTASIS; LIPID METABOLISM; LIVER; LIVER CELL; LIVER CELL CARCINOMA; LIVER FUNCTION; LOSS OF FUNCTION MUTATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROCESSING; RNA SPLICING; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GLUCOSE; HEP G2 CELLS; HEPATOCYTES; HOMEOSTASIS; HUMANS; LIPID METABOLISM; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; RIBONUCLEOPROTEINS, SMALL NUCLEAR; RNA SPLICING; TRANSCRIPTION FACTORS;

EID: 84903759888     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74382     Document Type: Article

References (71)

1. Costa RH, Kalinichenko VV, Holterman A-XL, Wang X. Transcription factors in liver development, differentiation, and regeneration. Hepatology. 2003;38(6):1331-1347. (Pubitemid 37466956)
2. Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58(3):593-608.
3. Michalopoulos GK. Principles of liver regeneration and growth homeostasis. Compr Physiol. 2013;3(1):485-513.
4. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6:425-456.
5. Avila MA, et al. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol. 2000;33(6):907-914.
6. Okabe H, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 2001;61(5):2129-2137. (Pubitemid 32692038)
7. Berasain C, et al. Expression of Wilms' tumor suppressor in the liver with cirrhosis: relation to hepatocyte nuclear factor 4 and hepatocellular function. Hepatology. 2003;38(1):148-157. (Pubitemid 36775806)
8. Perugorría MJ, et al. Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy. Cancer Res. 2009;69(4):1358-1367.
9. Becker D, et al. Genetic signatures shared in embryonic liver development and liver cancer define prognostically relevant subgroups in HCC. Mol Cancer. 2012;11:55.
10. Behnke M, Reimers M, Fisher R. The expression of embryonic liver development genes in hepatitis C induced cirrhosis and hepatocellular carcinoma. Cancers (Basel). 2012;4(3):945-968.
11. Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis. 2008; 29(7):1299-1305.
12. Lerose R, Molinari R, Rocchi E, Manenti F, Villa E. Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Eur J Cancer. 2001;37(2):239-245. (Pubitemid 32144702)
13. Lee J-S, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12(4):410-416.
14. Hoshida Y, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359(19):1995-2004.
15. Li J, Ning G, Duncan SA. Mammalian hepatocyte differentiation requires the transcription factor HNF-4α. Genes Dev. 2000;14(4):464-474. (Pubitemid 30131891)
16. Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ. Hepatocyte nuclear factor 4β(nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol. 2001;21(4):1393-1403.
17. Lazarevich NL, et al. Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology. 2004; 39(4):1038-1047. (Pubitemid 38428943)
18. Sen S, Jumaa H, Webster NJG. Splicing factor SRSF3 is crucial for hepatocyte differentiation and metabolic function. Nat Commun. 2013;4:1336.
19. Yea S, et al. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology. 2008;134(5):1521-1531. (Pubitemid 351615359)
20. Muñoz U, et al. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1. Mol Cancer Res. 2012; 10(9):1216-1227.
21. Chettouh H, et al. Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors. Cancer Res. 2013;73(13):3974-3986.
22. Berasain C, et al. Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences. World J Gastroenterol. 2010;16(25):3091-3102.
23. Reed R. Mechanisms of fidelity in pre-mRNA splicing. Curr Opin Cell Biol. 2000;12(3):340-345. (Pubitemid 30265064)
24. Castillo J, et al. Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors. Gastroenterology. 2009;137(5):1805-15.e1-4.
25. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010;330(6009):1340-1344.
26. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21(3):297-308.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
28. Lareau LF, Inada M, Green RE, Wengrod JC, Brenner SE. Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements. Nature. 2007;446(7138):926-929. (Pubitemid 46633161)
29. Samanez CH, et al. The human hepatocyte cell lines IHH and HepaRG: models to study glucose, lipid and lipoprotein metabolism. Arch Physiol Biochem. 2012;118(3):102-111.
30. Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012; 92(4):1515-1542.
31. Ariel I, et al. The product of the imprinted H19 gene is an oncofetal RNA. Mol Pathol. 1997;50(1):34-44.
32. Madec S, et al. CYP4F3B expression is associated with differentiation of HepaRG human hepatocytes and unaffected by fatty acid overload. Drug Metab Dispos. 2011;39(10):1987-1996.
33. Santamaría M, et al. Nuclear α1-antichymotrypsin promotes chromatin condensation and inhibits proliferation of human hepatocellular carcinoma cells. Gastroenterology. 2013;144(4):818-828.e4.
34. Hai T, Wolfgang CD, Marsee DK, Allen AE, Sivaprasad U. ATF3 and stress responses. Gene Expr. 1999;7(4-6):321-335. (Pubitemid 29372076)
35. Derdak Z, et al. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol. 2013;58(4):785-791.
36. Nordlie RC, Foster JD, Lange AJ. Regulation of glucose production by the liver. Annu Rev Nutr. 1999; 19:379-406. (Pubitemid 29380610)
37. Frasca F, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 1999;19(5):3278-3288. (Pubitemid 29193789)
38. Yuneva MO, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012;15(2):157-170.
39. Panasyuk G, et al. PPARαcontributes to PKM2 and HK2 expression in fatty liver. Nat Commun. 2012; 3:672-679.
40. Torres-Padilla ME, Fougère-Deschatrette C, Weiss MC. Expression of HNF4βisoforms in mouse liver development is regulated by sequential promoter usage and constitutive 3′αend splicing. Mech Dev. 2001;109(2):183-193. (Pubitemid 33112031)
41. Zhang X, et al. Genome-wide analysis of cAMPresponse element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci U S A. 2005; 102(12):4459-4464. (Pubitemid 40397134)
42. Amelio AL, et al. A coactivator trap identifies NONO (p54nrb) as a component of the cAMPsignaling pathway. Proc Natl Acad Sci U S A. 2007; 104(51):20314-20319.
43. Leahy P. CREB binding protein coordinates the function of multiple transcription factors including nuclear factor I to regulate phosphoenolpyruvate carboxykinase (GTP) gene transcription. J Biol Chem. 1999;274(13):8813-8822. (Pubitemid 29164680)
44. Duong DT, Waltner-Law ME, Sears R, Sealy L, Granner DK. Insulin inhibits hepatocellular glucose production by utilizing liver-enriched transcriptional inhibitory protein to disrupt the association of CREB-binding protein and RNA polymerase II with the phosphoenolpyruvate carboxykinase gene promoter. J Biol Chem. 2002;277(35):32234-32242. (Pubitemid 34969039)
45. Altarejos JY, Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol. 2011;12(3):141-151.
46. Raghow R, Yellaturu C, Deng X, Park EA, Elam MB. SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metabol. 2008;19(2):65-73. (Pubitemid 351317897)
47. Haas JT, et al. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metab. 2012;15(6):873-884.
48. Wan M, et al. A noncanonical, GSK3-independent pathway controls postprandial hepatic glycogen deposition. Cell Metab. 2013;18(1):99-105.
49. Khamzina L, Gruppuso PA, Wands Jr. Insulin signaling through insulin receptor substrate 1 and 2 in normal liver development. Gastroenterology. 2003;125(2):572-585. (Pubitemid 36929438)
50. Briançon N, Weiss MC. In vivo role of the HNF4α AF-1 activation domain revealed by exon swapping. EMBO J. 2006;25(6):1253-1262.
51. Chua K, Reed R. The RNA splicing factor splice-site choice.?hSlu7 is required for correct 3′ Nature. 1999;402(6758):207-210.
52. Shomron N, Alberstein M, Reznik M, Ast G. Stress alters the subcellular distribution of hSlu7 and thus modulates alternative splicing. J Cell Sci. 2005;118(pt 6):1151-1159. (Pubitemid 40528686)
53. Nakhei H, Lingott A, Lemm I, Ryffel GU. An alternative splice variant of the tissue specific transcription factor HNF4βpredominates in undifferentiated murine cell types. Nucleic Acids Res. 1998; 26(2):497-504. (Pubitemid 28291575)
54. Tanaka T, et al. Dysregulated expression of P1 and P2 promoter-driven hepatocyte nuclear factor-4βin the pathogenesis of human cancer. J Pathol. 2006;208(5):662-672.
55. Rhee J, et al. Regulation of hepatic fasting response by PPARα coactivator-1β(PGC-1): requirement for hepatocyte nuclear factor 4βin gluconeogenesis. Proc Natl Acad Sci U S A. 2003;100(7):4012-4017. (Pubitemid 36418148)
56. Bonzo JA, Ferry CH, Matsubara T, Kim J-H, Gonzalez FJ. Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4βin adult mice. J Biol Chem. 2012;287(10):7345-7356.
57. Hanse EA, et al. Cyclin D1 inhibits hepatic lipogenesis via repression of carbohydrate response element binding protein and hepatocyte nuclear factor 4α. Cell Cycle. 2012;11(14):2681-2690.
58. Walesky C, et al. Hepatocyte nuclear factor 4 βdeletion promotes diethylnitrosamine-induced hepatocellular carcinoma in rodents. Hepatology. 2013; 57(6):2480-2490.
59. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 2010;463(7279):364-368.
60. Webster NJ, et al. Differential effects of Wilms tumor WT1 splice variants on the insulin receptor promoter. Biochem Mol Med. 1997;62(2):139-150. (Pubitemid 28063390)
61. Jitrapakdee S. Transcription factors and coactivators controlling nutrient and hormonal regulation of hepatic gluconeogenesis. Int J Biochem Cell Biol. 2012;44(1):33-45.
62. Allen-Jennings AE, Hartman MG, Kociba GJ, Hai T. The roles of ATF3 in glucose homeostasis. A transgenic mouse model with liver dysfunction and defects in endocrine pancreas. J Biol Chem. 2001; 276(31):29507-29514.
63. Pei L, et al. NR4A orphan nuclear receptors are transcriptional regulators of hepatic glucose metabolism. Nat Med. 2006;12(9):1048-1055. (Pubitemid 44353386)
64. Lau JS, et al. Heterogeneous nuclear ribonucleoproteins as regulators of gene expression through interactions with the human thymidine kinase promoter. J Cell Biochem. 2000;79(3):395-406.
65. Ogawa S, et al. Three-dimensional culture and cAMP signaling promote the maturation of human pluripotent stem cell-derived hepatocytes. Development. 2013;140(15):3285-3296.
66. Zeng Y, Cai X, Cullen BR. Use of RNA polymerase II to transcribe artificial microRNAs. Meth Enzymol. 2005;392:371-380. (Pubitemid 40092526)
67. Kramer M. In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol Ther. 2003;7(3):375-385.
68. Gil-Fariña I, et al. IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expression. PLoS One. 2013; 8(7):e67748.
69. Zolotukhin S, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999; 6(6):973-985. (Pubitemid 29295202)
70. Fueger BJ, et al. Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med. 2006;47(6):999-1006. (Pubitemid 46939953)
71. Berasain C, et al. Amphiregulin: an early trigger of liver regeneration in mice. Gastroenterology. 2005;128(2):424-432. (Pubitemid 40431094)